Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02942290 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
A Phase 1 study of Myelodysplastic Syndromes (MDS), sponsored by AbbVie.
- Active
- Registry status
- Phase 1
- Development phase
- 129
- Enrollment target
- 20
- Study locations
NCT02942290: Active Phase 1 study of Myelodysplastic Syndromes (MDS), sponsored by AbbVie.
NCT02942290 is a Phase 1 study of Myelodysplastic Syndromes (MDS) that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 129 participants, below the 177-participant average among 10 other Myelodysplastic Syndromes (MDS) trials with a reported enrollment target (27% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02942290, a Phase 1 study of Myelodysplastic Syndromes (MDS), is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 129 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in participants with treatment-naïve higher-risk MDS comprising a dose-escalation portion and a safety expansion portion.
Primary Outcome
Area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration (AUCt) for azacitidine.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Azacitidine
Study Locations (20)
New South Wales
- Concord Repatriation General Hospital /ID# 154958 - Concord
- Duplicate_St. Vincent's Hospital, Darlinghurst /ID# 222846 - Darlinghurst
- St George Hospital /ID# 154954 - Kogarah
- Liverpool Hospital /ID# 222410 - Liverpool
- Calvary Mater Newcastle /ID# 154957 - Waratah
Massachusetts
- Tufts Medical Center /ID# 153672 - Boston
- Dana-Farber Cancer Institute /ID# 152735 - Boston
New York
- Columbia University Medical Center /ID# 153661 - New York
- Weill Cornell Medical College /ID# 155524 - New York
Tennessee
- Tennessee Oncology-Nashville Centennial /ID# 222769 - Nashville
- Vanderbilt University Medical Center /ID# 152738 - Nashville
Arizona
- Duplicate_University of Arizona Cancer Center - North Campus /ID# 154155 - Tucson
Illinois
- The University of Chicago Medical Center /ID# 153673 - Chicago
Maryland
- University of Maryland, Baltimore /ID# 153669 - Baltimore
Missouri
- Washington University-School of Medicine /ID# 153671 - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2017-01-12 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
What the registry record for NCT02942290 still lists
NCT02942290 is an interventional study that assigns participants to a tested intervention. The registered 129 participants enrollment target is mid-sized for trials with a published cap, below the 177-participant average among 10 other Myelodysplastic Syndromes (MDS) trials with a reported enrollment target (27% lower).
The record links to 1 condition, with Myelodysplastic Syndromes (MDS) appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.
NCT02942290 names 20 study sites across 13 states, led by New South Wales, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT02942290 about?
NCT02942290 is a clinical study titled "A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)". This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in participants with treatment-naïve higher-risk MDS comprising a dose-escalation portion and a safety expansion portion.
What is the current status of trial NCT02942290?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 129 participants. The study started on 2017-01-12. Estimated completion is 2027-01.
What conditions does trial NCT02942290 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes (MDS).
What interventions are being tested in trial NCT02942290?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG).
Who is sponsoring clinical trial NCT02942290?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02942290 being conducted?
This trial has 20 study locations across Arizona, Illinois, Maryland, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes (MDS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02942290's enrollment target sits among peer trials
129 4th of 10 higher than 7 of 10 other Myelodysplastic Syndromes (MDS) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelodysplastic Syndromes (MDS) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
RECRUITING · Phase 1
-
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
RECRUITING · Phase 1
-
Cord Blood Transplant in Adults With Blood Cancers
RECRUITING · Phase 2
-
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
RECRUITING · Phase 3
-
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RECRUITING · Early Phase 1
-
Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03619850 · 129 participants · Phase 3
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- NCT05704361 · 129 participants · Phase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
- NCT05919849 · 129 participants · Phase 1
Supporting Parents in Affirming Their Children's Experiences of Stigma
- NCT06313749 · 129 participants · NA
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI